Primary open-angle glaucoma

American Journal of Nursing

Volumn 109, Issue 2, 2009, Pages 40-47

  Sharts Hopko, Nancy C ^a,b   Glynn Milley, Catherine ^b  

^a University College of Nursing   (United States)

^b Affairs Palo Alto Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60749125824     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAJ.0000345434.37734.ee     Document Type: Article

References (78)

1. American Academy of Ophthalmology Glaucoma Panel. Primary open-angle glaucoma. Preferred Practice Patterns. San Francisco: American Academy of Ophthalmology; 2005. http://one.aao.org/asset.axd?id=2e86ca2e-9db0-43c9-b605- c004a82b6ea5.
2. Friedman DS, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004;138(3 Suppl):S19-S31.
3. Chopra V, et al. Type 2 diabetes mellitus and the risk of open-angle glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 2008;115(2):227-32.
4. Cross JM, et al. The association between thyroid problems and glaucoma. Br J Ophthalmol 2008;92(11):1503-5.
5. Fan BJ, et al. Genetic and environmental risk factors for primary open-angle glaucoma. Chin Med J (Engl) 2004;117(5): 706-10.
6. Girkin CA, et al. Hypothyroidism and the development of open-angle glaucoma in a male population. Ophthalmology 2004;111(9):1649-52.
7. Klein BE, et al. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005;89(3):284-7.
8. Pasquale LR, et al. Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 2006;113(7):1081-6.
9. Tatemichi M, et al. Possible association between heavy computer users and glaucomatous visual field abnormalities: a cross sectional study in Japanese workers. J Epidemiol Community Health 2004;58(12):1021-7.
10. Tripathi RC, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999;15(6):439-50.
11. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363(9422):1711-20.
12. Vision 2020. What is avoidable blindness? Glaucoma. London: International Agency for the Prevention of Blindness; World Health Organization; n.d.; http://www.v2020.org/page.asp?section=0001000100020009.
13. Friedman DS, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122(4):532-8.
14. Congdon N, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122(4):477-85.
15. Quigley HA, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119(12):1819- 26.
16. Wolfs RC, et al. Changing views on open-angle glaucoma: definitions and prevalences - the Rotterdam Study. Invest Ophthalmol Vis Sci 2000;41(11):3309-21.
17. Hulsman CA, et al. Is open-angle glaucoma associated with early menopause? The Rotterdam Study. Am J Epidemiol 2001;154(2):138-44.
18. National Eye Institute. National Plan for Eye and Vision Research: glaucoma and optic neuropathies program. Bethesda, MD; 2006 Dec. http://www.nei.nih.gov/strategicplanning/np-glaucoma.asp.
19. Harby K. Intraocular pressure fluctuation is a risk factor for visual loss in glaucoma patients. Medscape Medical News 2003 Nov 18. http://www.medscape.com/viewarticle/464687.
20. Lichter PR, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108(ll):1943-53.
21. Nouri-Mahdavi K, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111(9):1627-35.
22. Bengtsson B, et al. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology 2007;114(2):205-9.
23. Caprioli J, Coleman AL. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology 2008;115(7):1123-29.
24. Medeiros FA, et al. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology 2008;115(6):934-40.
25. Heijl A, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-79.
26. Miglior S, et al. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112(3):366-75.
27. Fleming C, et al. Screening for primary open-angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force. Ann Fam Med 2005;3(2): 167-70.
28. Ang GS, Eke T. Lifetime visual prognosis for patients with primary open-angle glaucoma. Eye 2007;21(5):604-8.
29. Spaeth G, et al. Evaluation of quality of life for patients with glaucoma. Am J Ophthalmol 2006;141(1 Suppl):S3-S14.
30. American Academy of Ophthalmology Preferred Practice Patterns Committee. Comprehensive adult medical eye evaluation. San Francisco: American Academy of Ophthalmology; 2005. http://one.aao.org/asset.axd?id=6749e4a0-6a09- 4795-8f8d-aec60dc937c9.
31. National Eye Institute. Report of the Glaucoma Panel: program overview and goals. Bethesda, MD; 2006. http://www.nei.nih.gov/resources/ strategicplans/neiplan/frm-glaucoma.asp.
32. Prevent Blindness America. Vision problems in the U.S. Prevalence of adult vision impairment and age-related eye disease in America [2008 update to the fourth edition]. Chicago; 2008. http://www.preventblindness.org/vpus/ 2008-update/VPUS-2008-update.pdf.
33. Kass MA, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701-13.
34. Leske MC, et al. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112(6):821-9.
35. National Guideline Clearinghouse. Primary open-angle glaucoma suspect. Rockville, MD: Agency for Healthcare Research and Quality; 2005. http://www.guideline.gov/summary/summary.aspx?doc-id=8202&nbr= 004577&string=glaucoma.
36. Stjernschantz J, et al. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res 2000;19(4):459-96.
37. Toris CB, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997;41 Suppl 2:S69-S75.
38. Higginbotham EJ, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120(7):915-22.
39. Netland PA, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132(4):472-84.
40. Alward WL. Medical management of glaucoma. N Engl J Med 1998;339(18):1298-307.
41. Camras CB, Sheu WP. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma 2005;14(2):161-7.
42. Cantor L. Achieving low target pressures with today's glaucoma medications. Surv Ophthalmol 2003;48 Suppl 1:S8-S16.
43. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000;22(2):167-208.
44. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19(1):87-112.
45. Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician 2003;67(9):1937-44.
46. McKinnon SJ, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care 2008;14(1 Suppl):S20-S27.
47. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye 2006;20(4):407-16.
48. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005;5(5):459-63.+
49. Ventura MT, et al. Hypersensitivity reactions to ophthalmic products. Curr Pharm Des 2006;12(26):3401-10.
50. Latina MA, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol 2002;13(2):94-6.
51. National Eye Institute. Laser surgery is safe and effective first treatment for glaucoma [press release]. 1995 Dec 15. http://www.nei.nih.gov/ news/pressreleases/gltpressrelease.asp.
52. Chen CW, et al. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. J Ocul Pharmacol 1990;6(3):175-82.
53. Shingleton BJ, et al. Long-term efficacy of argon laser trabeculoplasty. A 10-year follow-up study. Ophthalmology 1993;100(9):1324-9.
54. Rolim de Moura C, et al. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007;(4):CD003919.
55. Glaucoma Research Foundation. Glaucoma surgery, n.d. http://www.glaucoma.org/treating/surgery.php.
56. Chen TC, et al. Long-term follow-up of initially successful trabeculectomy. Ophthalmology 1997;104(7):1120-5.
57. Zacharia PT, et al. Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol 1993;116(3):314-26.
58. University of Maryland Medical Center. Glaucoma: surgery. 2007. http://www.umm.edu/patiented/articles/what-surgical-treatments-glaucoma-000025- 9.htm.
59. Bartamian M, Higginbotham EJ. What is on the horizon for cycloablation? Curr Opin Ophthalmol 2001;12(2):119-23.
60. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 2006;17(2):190-5.
61. Kharod BV, et al. Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients. J Glaucoma 2006;15(3):244-7.
62. Muir KW, et al. Health literacy and adherence to glaucoma therapy. Am J Ophthalmol 2006;142(2):223-6.
63. Prevent Blindness America. The vision learning center: taking eye drop medicine. 2004. http://www.preventblindness.org/vlc/eye-drops.html.
64. Brody S, et al. Intraocular pressure changes: the influence of psychological stress and the Valsalva maneuver. Biol Psychol 1999;51(l):43-57.
65. Kaluza G, et al. Stress reactivity of intraocular pressure after relaxation training in open-angle glaucoma patients. J Behav Med 1996;19(6):587-98.
66. Gallardo MJ, et al. Progression of glaucoma associated with the Sirsasana (headstand) yoga posture. Adv Ther 2006; 23(6):921-5.
67. Hannuksela ML, Ellahham S. Benefits and risks of sauna bathing. Am J Med 2001;110(2):118-26.
68. Bonovas S, et al. Epidemiological association between cigarette smoking and primary open-angle glaucoma: a metaanalysis. Public Health 2004;118(4):256-61.
69. Avisar R, et al. Effect of coffee consumption on intraocular pressure. Ann Pharmacother 2002;36(6):992-5.
70. Tomida I, et al. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 2006;15(5):349-53.
71. American Academy of Ophthalmology Task Force on Complementary Therapies. Marijuana in the treatment of glaucoma. San Francisco: American Academy of Ophthalmology; 2003. http://www.eyecareamerica.org/eyecare/treatment/ alternative-therapies/marijuanaglaucoma.cfm.
72. Dane S, et al. Long-term effects of mild exercise on intraocular pressure in athletes and sedentary subjects. Int J Neurosci 2006;116(10):1207-14.
73. Mori K, et al. Relationship between intraocular pressure and obesity in Japan. Int J Epidemiol 2000;29(4):661-6.
74. Teng C, et al. Effect of a tight necktie on intraocular pressure. Br J Ophthalmol 2003;87(8):946-8.
75. Bertsch A, et al. The sensing contact lens. Med Device Technol 2006;17(5):19-21.
76. UC Davis News Service. Smart contact lenses [press release]. 2008 Jul 30. http://www.news.ucdavis.edu/search/news-detail.lasso?id=8722.
77. Dinn RB, et al. Ocular changes in pregnancy. Obstet Gynecol Surv 2003;58(2):137-44.
78. Owsley C, McGwin G, Jr. Vision impairment and driving. Surv Ophthalmol 1999;43(6):535-50.